YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[View of Moderna office entrance with logo sign, Biotechnology industry] Veronique D Shares of Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) have rallied 202% since Aug. 18, fueled by positive news about the biotech company's exper…
Check out the companies making the biggest moves premarket: Fair Isaac — Shares plunged 18% after Federal Housing Finance Agency director Bill Pulte introduced changes to mortgage pricing. "We are Simplifying Mortgage Pricing following fee…
Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says. Continue Reading
Quick Read MRNA has surged 506% in 2026 on a top-line win from the 1,137-patient INTerpath-001 melanoma trial, with full Phase 3 data due October 24. BNTX's 5% gain versus Moderna's 506% confirms the market is betting on intismeran specifi…
Quick Read Moderna surged 9% to $168 after its Phase 3 melanoma vaccine study earned the ESMO congress's highest-profile Presidential Symposium slot on October 24. Merck gained just 1% and BioNTech 2%, signaling the market views this as a…
Quick Read Moderna surged 5% to $152.83, extending a stunning 137% one-month run fueled solely by its Phase 2b melanoma vaccine data showing a 49% reduction in recurrence risk. BioNTech edged up just 1% despite running a rival mRNA cancer…
A sharp reversal in crude oil handed U.S. equities a reprieve on Wednesday, with stocks grinding higher off six-week lows just hours before the Federal Reserve is expected to raise interest rates for the first time since 2023. The S&P 500…
Quick Read IBB surged 26% over three months versus SPY's 4%, as big pharma's price-insensitive buyouts of patent-cliff replacements rewarded IBB holders. XBI's equal-weight design returned 34% YTD versus IBB's 26%, making it the higher-tor…
Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built for investors. If a sector rallies in a forest and no one's there to hear it, does it really cash in? Moderna turned investors' heads a…
Quick Read MRNA climbed 6% as traders read GSK's Phase III mRNA flu commitment as platform validation rather than a competitive threat to mFlusvia. Moderna's Phase III melanoma win with MRK as co-developer rekindled platform interest, and…
Quick Read NVAX jumped 7% on unverified Matrix-M oncology speculation, even as the real story had already quietly resumed: high-teens royalties on Sanofi's Nuvaxovid global net sales restarted for 2026 and 2027. IBB gained just 0.2% while…
Quick Read Moderna shed 7% of Tuesday's 14% Wolfe Research upgrade rally, while BioNTech's 2% dip confirms the selloff is Moderna-specific. IBB barely moved while Moderna's $59 billion cap prices in Merck's unapproved intismeran program ag…
Quick Read MRK surged 45% year to date to $156, but Wall Street's consensus target sits at $148, requiring a clean fall catalyst sweep to reach $200. MRNA soared 157% in a month as Merck's cancer vaccine partner ahead of pivotal ESMO melan…
[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [http…
Quick Read MRNA drops 7% to $135 after a 392% YTD surge, as traders book profits with no new negative catalysts driving the decline. Partner MRK gained 47% YTD on Keytruda's label expansion potential, while BNTX trails at 22% amid a slower…
Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company’s investigational therapy for Hunter syndome. Continue Reading
[Patients Receiving Medical Infusions in a Clinical Setting with Nurse Assistance] FatCamera/iStock via Getty Images Earlier this week, shares of Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and partner Merck (MRK [https://seeking…
Key Points Interested in Eli Lilly and Company? Here are five stocks we like better. Moderna's mRNA cancer vaccine, developed with Merck, succeeded in a late-stage melanoma trial, sending shares up 177% and boosting the broader biotech sec…
Investors are sensitive to any policy pronouncements from Federal Reserve Chairman Kevin Warsh (left) or Treasury Secretary Scott Bessent, as yields on long-term U.S. Treasury bonds rise. - MarketWatch photo illustration/Getty Images, iSto…
Moderna (MRNA) stock doubled on Wednesday and stole the show. But healthcare had already been quietly breaking out for months — just as chips were sliding into a bear market. Since semiconductors peaked on June 22, the iShares Biotechnolog…
Biotechnology Moderna's eye-popping surge on Wednesday didn't just reward holders of the stock. It supercharged what was already one of the strongest corners of the market this year: biotech and pharma. Moderna and Merck said their persona…
Quick Read Moderna (MRNA) dropped 20% Thursday, reversing part of Wednesday's 177% surge, while BioNTech (BNTX) fell 4% on diminishing read-across enthusiasm. The complete intismeran dataset, due at ESMO in Madrid from October 23 to 27, wi…
Moderna (MRNA) and Merck (MRK) reported promising results in their melanoma vaccine trial, sending the stocks soaring. BD8 Capital Partners CEO and CIO Barbara Doran and Yahoo Finance Markets and Data Editor Jared Blikre chat with Yahoo Fi…
[US 100 dollar bill folded into an up arrow on wooden table. Illustration of the concept of inflation, profit, earning and investment] Biotech stocks have reached their highest level since the height of the pandemic after Moderna (MRNA [ht…
The stock jumps after a melanoma treatment has success in a late-stage trial. One analyst says annual sales could hit $3 billion by 2035. Continue Reading
Check out the companies making the biggest moves premarket: Moderna , Merck — Shares of the pharmaceutical companies surged after a personalized cancer vaccine between the two companies showed positive results in a late-stage trial . Moder…
Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.8%.The iShares Biotechnology ETF (IBB) was up 1%.In corporate news, Haemonetic…
Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 1.8% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.7%.The iShares Biotechnology ETF (IBB) was up 0.8%.In corporate news, Amylyx…
Bio-Techne ground sign outside of the office in San Jose, California, USA - June 8, 2023_ By JHVEPhoto Bio-Techne Corporation (TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and sells life science reagents, instrum…
Healthcare stocks were mixed Monday afternoon, with the NYSE Healthcare Index up nearly 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) fractionally lower.The iShares Biotechnology ETF (IBB) climbed up 1.8%.In corporate…
[Wall Street in New York City] JaysonPhotography/iStock via Getty Images Bank of America Securities is urging investors to look beyond crowded artificial intelligence trades, arguing that value stocks, biotech, regional banks, select credi…
Launched on June 23, 2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market. While an excellent vehicle f…
Quick Read LEGN surged 6% as Q2 revenue of $388M beat estimates and adjusted EPS of $0.16 doubled consensus, marking the company's first-ever profitable quarter. CARVYKTI net sales hit $657M, up 50%, with JNJ co-developer Janssen supportin…
[Medical research with pipette and test tube, DNA analysis, biotechnology, genetic science and healthcare] jittawit.21 Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY [ht…
Moderna Inc. (NASDAQ:MRNA) stock rose in Wednesday premarket trading after gaining 3.4% in the previous session, as investors reacted to the company's latest progress in expanding its infectious disease pipeline with an investigational Ebo…
Moderna Inc HQ-by hapabapa via iStock Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company focused on developing medicines and vaccines using messenger RNA (mRNA) technology. Valued at a market cap of $18.4 billio…